Precision Biosciences, Inc.
Clinical trials sponsored by Precision Biosciences, Inc., explained in plain language.
-
Gene-Editing breakthrough: could PBGENE-DMD fix duchenne at its source?
Disease control Recruiting nowThis early-stage trial tests a one-time gene-editing treatment called PBGENE-DMD in 18 boys aged 2-7 with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and can restore dystrophin, a protein missing in DMD. The treatment aims to correct the genetic error by r…
Phase: PHASE1, PHASE2 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Gene-Editing breakthrough targets chronic hepatitis b in first human trial
Disease control Recruiting nowThis early-stage study tests a new gene-editing drug called PBGENE-HBV in 45 adults with chronic hepatitis B who are already on antiviral medication. The goal is to see if the treatment is safe and can help control the virus. Participants must be in good health and have no liver …
Phase: PHASE1 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC